About A2M TF
Established in 2016, the ECL Access to Medicines Task Force aims to make cancer medicines available for all cancer patients in Europe by insisting on accessibility, sustainability of the healthcare system and transparency of drug prices. The Task Force strongly believes in the power of dialogue. We urge all stakeholders to push for innovative improved treatments, improving both survival and the quality of life of cancer patients, instead of investments in me-too products. Currently, 25 national/regional cancer leagues, representing over 450 million Europeans, have signed the Task Force’s Declaration of Intent.
Introductory Word from the Task Force Chair
“Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it’s the only thing that ever has.” Margaret Mead
At the start of 2018, 25 partners in 23 European countries have endorsed the idea that all cancer patients in Europe should have access to medicines. A great achievement if we look back at the Spring of 2016, when a committed group 5 cancer societies together with the ECL Secretariat created the ECL Access to Medicines Task Force.
However, we are still at the beginning of our journey. Although our alliance has grown rapidly, our strength does not only come from the number of Europeans we represent. They stem from the power of our ideas and the willingness to create real change. Impact for those who need it most, when they need it most.
Now, more than ever, it is time for strategic and concrete action. We have the opportunity and the responsibility to assure sustainable access to medicine for all cancer patients. We will only achieve our goals by working together. We therefore hope that in the future, more and more organisations will feel empowered to join us in action.
The ultimate goal of the task force is to “achieve equal access to medicines for all cancer patients in Europe”. To achieve our mission, we have formulated and agreed on 5 long term goals stated in the Declaration of Intent.
Chair, ECL Access to Medicines Task Force